Successful trials of an AIDS vaccine
The vaccine against AIDS created by Spanish scientists has demonstrated excellent results during the first phase of clinical trials. These results are considerably better than the data obtained from other experiments with similar drugs. The vaccine stimulates the body's defense system and "teaches" immune cells to recognize HIV infection and fight it, says El Mundo.
In order to create the vaccine, 4 human immunodeficiency virus genes were used. They were sufficient, as it turned out, to induce protective immune responses, without triggering the development of a disease, writes El Mundo.
During the course of the study, which lasted almost 10 years, it was established that in 90% of cases the vaccine against AIDS causes a strong immune response, which may well prevent the patient from getting infected. This immunity is retained for one year in 85% of the experiment's subjects.
At this stage in the study it was confirmed that the immune response to the vaccine is strong, and it does not cause any dangerous side effects. The authors of the study argue that this data is not sufficient to predict whether this vaccine can prevent HIV infection. Additional clinical trials are required.
The obtained results, however, instill hopes that such a vaccine could be used for therapeutic purposes by patients with AIDS.